<DOC>
	<DOCNO>NCT02278978</DOCNO>
	<brief_summary>BIBF1120 patient advance FGFR3 mutate , FGFR3 overexpressed , FGFR3 wild type urothelial carcinoma urinary bladder , urethra , ureter , renal pelvis fail platinum-based chemotherapy .</brief_summary>
	<brief_title>BIBF1120 Patients With Advanced FGFR3 Mutated , Overexpressed , Wild Type Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>KPS 60 % Histological confirmation urothelial carcinoma , metastatic disease Measurable disease Previously treat platinumbased chemotherapy administer Radiographic evidence cavitary necrotic tumour Active brain metastasis.Leptomeningeal metastasis Chemotherapy , radiotherapy , target therapy monoclonal antibody small tyrosine kinase inhibitor Grade 1 treatmentrelated toxicity previous chemotherapy , radiotherapy , target therapy Prior treatment BIBF 1120 VEGFR inhibitor Significant cardiovascular disease : Pericardial effusion Significant bleeding thrombosis Gastrointestinal disorder abnormality would interfere absorption study drug Major injury within past 10 day incomplete wound heal and/or plan surgery ontreatment study period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>urothelial carcinoma</keyword>
	<keyword>BIBF1120</keyword>
</DOC>